BlackRock’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-1,461,881
| Closed | -$308K | – | 5574 |
|
|
2023
Q2 | $308K | Buy |
1,461,881
+352
| +0% | +$61 | ﹤0.01% | 4622 |
|
|
2023
Q1 | $234K | Sell |
1,461,529
-123,894
| -8% | -$55K | ﹤0.01% | 4732 |
|
|
2022
Q4 | $880K | Sell |
1,585,423
-695,224
| -30% | -$591K | ﹤0.01% | 4449 |
|
|
2022
Q3 | $2.71M | Sell |
2,280,647
-24,839
| -1% | -$26.8K | ﹤0.01% | 4038 |
|
|
2022
Q2 | $1.46M | Sell |
2,305,486
-4,263,924
| -65% | -$3.27M | ﹤0.01% | 4382 |
|
|
2022
Q1 | $7.49M | Sell |
6,569,410
-98,093
| -1% | -$117K | ﹤0.01% | 3735 |
|
|
2021
Q4 | $15M | Buy |
6,667,503
+684,014
| +11% | +$1.72M | ﹤0.01% | 3440 |
|
|
2021
Q3 | $20.5M | Sell |
5,983,489
-57,855
| -1% | -$178K | ﹤0.01% | 3259 |
|
|
2021
Q2 | $18.1M | Buy |
6,041,344
+4,035,328
| +201% | +$12.8M | ﹤0.01% | 3364 |
|
|
2021
Q1 | $6.48M | Buy |
2,006,016
+1,029,570
| +105% | +$3.43M | ﹤0.01% | 3819 |
|
|
2020
Q4 | $2.07M | Buy |
976,446
+5,748
| +0.6% | +$9.48K | ﹤0.01% | 4037 |
|
|
2020
Q3 | $1.14M | Buy |
970,698
+57
| +0% | +$59 | ﹤0.01% | 4084 |
|
|
2020
Q2 | $878K | Buy |
970,641
+3,284
| +0.3% | +$3.13K | ﹤0.01% | 4072 |
|
|
2020
Q1 | $810K | Sell |
967,357
-2,150
| -0.2% | -$2.49K | ﹤0.01% | 3943 |
|
|
2019
Q4 | $931K | Sell |
969,507
-465
| -0% | -$510 | ﹤0.01% | 4017 |
|
|
2019
Q3 | $999K | Sell |
969,972
-4,045
| -0.4% | -$5.51K | ﹤0.01% | 3982 |
|
|
2019
Q2 | $1.75M | Buy |
974,017
+854
| +0.1% | +$1.38K | ﹤0.01% | 3821 |
|
|
2019
Q1 | $1.83M | Sell |
973,163
-5,585
| -0.6% | -$8.17K | ﹤0.01% | 3738 |
|
|
2018
Q4 | $1.16M | Buy |
978,748
+625
| +0.1% | +$1.12K | ﹤0.01% | 3835 |
|
|
2018
Q3 | $2.65M | Buy |
978,123
+5,870
| +0.6% | +$12.1K | ﹤0.01% | 3680 |
|
|
2018
Q2 | $1.86M | Buy |
972,253
+20,352
| +2% | +$41.1K | ﹤0.01% | 3770 |
|
|
2018
Q1 | $2M | Sell |
951,901
-5,940
| -0.6% | -$12.7K | ﹤0.01% | 3674 |
|
|
2017
Q4 | $1.94M | Sell |
957,841
-54,520
| -5% | -$113K | ﹤0.01% | 3700 |
|
|
2017
Q3 | $1.35M | Buy |
1,012,361
+98,901
| +11% | +$123K | ﹤0.01% | 3815 |
|
|
2017
Q2 | $1.44M | Sell |
913,460
-2,087,591
| -70% | -$4.03M | ﹤0.01% | 3761 |
|
|
2017
Q1 | $9.69M | Buy |
3,001,051
+2,920,394
| +3,621% | +$7.19M | ﹤0.01% | 3119 |
|
|
2016
Q4 | $108K | Sell |
80,657
-27,301
| -25% | -$35.7K | ﹤0.01% | 2499 |
|
|
2016
Q3 | $168K | Hold |
107,958
| – | – | ﹤0.01% | 2280 |
|
|
2016
Q2 | $143K | Buy |
107,958
+104,686
| +3,199% | +$490K | ﹤0.01% | 2300 |
|
|
2016
Q1 | $17K | Buy |
3,272
+1,944
| +146% | +$11.9K | ﹤0.01% | 2932 |
|
|
2015
Q4 | $10K | Sell |
1,328
-2,800
| -68% | -$24.1K | ﹤0.01% | 2901 |
|
|
2015
Q3 | $35K | Buy |
4,128
+2,800
| +211% | +$25.8K | ﹤0.01% | 2080 |
|
|
2015
Q2 | $14K | Sell |
1,328
-137
| -9% | -$1.76K | ﹤0.01% | 2599 |
|
|
2015
Q1 | $21K | Hold |
1,465
| – | – | ﹤0.01% | 2346 |
|
|
2014
Q4 | $25K | Hold |
1,465
| – | – | ﹤0.01% | 2262 |
|
|
2014
Q3 | $20K | Hold |
1,465
| – | – | ﹤0.01% | 2335 |
|
|
2014
Q2 | $19K | Sell |
1,465
-27
| -2% | -$281 | ﹤0.01% | 2413 |
|
|
2014
Q1 | $17K | Hold |
1,492
| – | – | ﹤0.01% | 2447 |
|
|
2013
Q4 | $21K | Hold |
1,492
| – | – | ﹤0.01% | 2348 |
|
|
2013
Q3 | $26K | Sell |
1,492
-3,632
| -71% | -$69.6K | ﹤0.01% | 2134 |
|
|
2013
Q2 | $84K | Buy |
+5,124
| New | +$159K | ﹤0.01% | 1716 |
|
Other funds holding INFI
BlackRock's INFI Position: Q3 2023 in Review
BlackRock sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2023, closing a stake of 1,461,881 shares — an estimated $308K sold.
BlackRock first reported a position in INFI in Q2 2013 and held it in 41 quarters. The position peaked at $20.5M in Q3 2021. 3 funds tracked by Wall St. Rank hold INFI as of Q3 2023.
- BlackRock reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- BlackRock sold 1,461,881 Infinity Pharmaceuticals, Inc. shares in Q3 2023, an estimated $308K.
- BlackRock first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 41 quarters.
- BlackRock's Infinity Pharmaceuticals, Inc. position peaked at $20.5M in Q3 2021.
- 3 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2023.
Based on BlackRock's 13F filing for Q3 2023, filed 13 Nov 2023.